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ABSTRAK 
 
KESAN SEVOFLURANE KE ATAS PARAS TAU PROTEIN DAN BRAIN 
DERIVED NEUROTROPIC FACTOR SELEPAS PEMBEDAHAN 
 
Objektif: Sevoflurane ialah gas yang seringkali digunakan dalam pembiusan penuh 
untuk memastikan pesakit berada dalam keadaan tidak sedar dan pembedahan dapat 
dijalankan dengan lancar. Secara amnya gas sevoflurane ini selamat digunakan untuk 
pembiusan pesakit namun terdapat kesan jangka panjang terhadap fungsi kognitif 
pesakit tersebut. Kesan penurunan fungsi kognitif ini telah dikaitkan apabila paras Tau 
Protein dan Brain Derived Neurotropic Factor didalam badan pesakit juga berkurangan 
selepas pembiusan menggunakan gas sevoflurane. Kajian ini adalah bertujuan untuk 
mengetahui kesan gas sevoflurance ke atas paras Tau Protein dan Brain Derived 
Neurotropic Factor di dalam badan pesakit selepas menjalani pembedahan yang 
menggunakan gas sevoflurane untuk pembiusan penuh. 
 
Methodologi: Kajian ini berbentuk prospektif keratan rentas ‘ cross sectional study ‘ 
yang  telah dijalankan di Dewan Bedah Hospital Universiti Sains Malaysia daripada 
bulan Jun 2013 sehingga Oktober 2014. Sebanyak 39 orang pesakit orthopaedic yang 
menjalani pembedahan menggunakan gas sevoflurane untuk pembiusan penuh telah 
terlibat didalam kajian ini. Sebelum pembiusan dijalankan, darah telah diambil untuk 
analisa penanda Tau Protein dan Brain Derived Neurotropic Factor. Ketika pembiusan 
dijalankan suhu badan pesakit dipastikan 36 – 37.5 °C untuk memastikan paras tau 
protein dan BDNF tidak terjejas disebabkan suhu yang sejuk. Sepanjang pembiusan am 
dijalankan menggunakan gas sevoflurane BIS digunakan untuk memastikan tahap MAC 
 
 
xii 
(konsentrasi alveolus minimum) gas Sevoflurane adalah 1.5 – 2.0 dengan campuran 
oksigen : udara, 70 : 30. Jangka masa pembedahan adalah diantara 60 – 180 minit. 
Selepas pembedahan dijalankan pesakit akan di ektubasi dan di letakkan di bilik 
pemerhatian. Pesakit akan dilihat oleh doctor bius dan memenuhi kriteria ALDRETE 
dan PADS skor sebelum di hantar ke wad. 24 - 48 jam seterusnya selepas pembedahan, 
satu lagi sampel darah telah diambil. Asai ELISA untuk plasma Protien Tau dan BDNF 
telah dilakukan untuk mendapatkan paras darah untuk penanda bio asas sebelum 
pembedahan dan selepas pembedahan yang menggunakan gas sevoflurane untuk 
pembiusan penuh.  
 
Keputusan:  Purata paras Tau protein sebelum menggunakan gas sevoflurane adalah 
18.63 ± SD 18.84 (purata ± SD) dan purata paras Tau Protein selepas menggunakan gas 
sevoflurane adalah 10.52 ± SD 18.52. Purata paras BDNF sebelum menggunakan gas 
sevoflurane adalah 1.63 ± SD 1.71 dan purata paras BDNF selepas menggunakan gas 
sevoflune adalah 1.40 ± SD 2.06.   Tiada sebarang perubahan ketara dapat dilihat dari 
segi paras Tau Protein atau Brain Derived Neurotropic Factor sebelum dan selepas 
pembedahan menggunakan gas sevoflurane. Ini menunjukkan bahawa tiada kesan 
keatas paras Tau Protein dan Brain Derived Neurotropic Factor pesakit selepas hanya 
sekali menjalani pembiusan menggunakan gas sevoflurane. 
 
Kesimpulan:  Kedua-dua paras Tau Protein dan Brain Derived Neurotropic Factor 
tidak berubah selepas hanya sekali menjalani pembiusan menggunakan gas sevoflurane.  
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ABSTRACT 
 
TAU PROTEIN AND BRAIN DERIVED NEUROTROPIC FACTOR PROFILE 
IN PATIENT UNDERGOING SEVOFLURANCE ANAESTHESIA 
 
Objective: Sevoflurane is commonly and widely used inhalational agent in general 
anaesthesia. The sevoflurane will be used in general anesthesia to ensure patients are 
not aware during the operation. Generally, anaesthesia using sevoflurance is safe but 
some study showed that the usage of sevoflurane can cause cognitive impairment post 
operatively in susceptible patient. The use of sevoflurane may cause deterioration in 
neurocognitive function resulting from tau hyperphosphorylation and perhaps reduced 
level of brain derived neurotropic factor. The purpose of this study is to investigate the 
effects of sevoflurane anaesthesia on the level of tau protein and brain derived 
neurotropic factor.  
 
Methodology: This was a cross-sectional observational study from June 2013 until 
October 2014 done in operation theatre Hospital Universiti Sains Malaysia (USM). 39 
patients scheduled to undergo elective surgery in orthopaedic cases requiring general 
anaesthesia were included. Blood was obtained for baseline tau protein and BDNF 
before induction of anaesthesia using sevoflurane. Maintenance of anaesthesia using 
sevoflurane with the target minimum alveolar concentration (MAC) 1.5 -2.0 in oxygen: 
air, 70:30 mixture and to achieved BIS reading of 40 – 60. Throughout the surgery body 
temperature are maintained within normal range (T° 36- 37.5 ). Duration of anaesthesia 
was planned for at least 60 and up to 180 min. Once operation is finished, patient will 
then be extubated and observed in recovery room & will be discharged to the respective 
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wards once they met the ALDRETE & PADSS score & reviewed by anaesthetist. Blood 
investigation for Tau Protein and BDNF will be repeated 24-48 hours postoperatively. 
ELISA assay for the plasma Tau protein and BDNF were performed to obtain the blood 
level for these biomarkers.  
 
Results:  The mean level of pre Tau Protein was 18.63 ± SD 18.84 and the mean level 
post Tau Protein was 10.52 ± SD 18.52. The mean level of pre BDNF was 1.63 ± SD 
1.71 and the mean level of post BDNF was 1.40 ± SD 2.06.  There were no significant 
changes in the level of Tau Protein or Brain Derived Neurotropic Factor before or after 
undergoing anaesthesia using sevoflurane. Postoperatively, there were no significant 
differences in the level of Tau Protein or Brain Derived Neurotropic Factor after first 
time exposure to sevoflurane anaesthesia. 
 
Conclusions: There were no significant differences on the level of both Tau Protein and 
Brain Derived Neurotropic Factor after first time exposure to sevoflurane anaesthesia.
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CHAPTER 1: INTRODUCTION 
 
For more than a half-century, anesthetics have been used in the clinical setting whilst 
their mechanisms of action on the brain remained unknown. The lipid theories of 
anesthesia (Meyer Overton rule) claimed that anesthetics produced loss of 
consciousness via direct interactions with the lipid bilayers of the neuronal membranes. 
It is well accepted now that anesthetics produce their effects on the CNS by modulating 
the activity of ligand- and/or gated ionic channels located on the neuronal membranes in 
the CNS. However, the mechanisms of anesthetic actions are complex, and considering 
only one ionic channel as the unique relevant target of anesthetics cannot account for 
the reported effects of these agents in the brain (Grasshoff C et al., 2005) 
 
Anesthetics given during surgery produce changes in the patient’s behavioral state by 
modifying brain activity via at least two mechanisms: dose-dependent global, and 
regionally specific, suppression of neuronal activity and disruption of functional 
interactivity within distributed neural networks (Heinke, W. and Koelsch, S. 2005). 
Neuronal nicotinic acetylcholine receptors (nAChRs) consist of different subunits, α 
and β, with different subtype arrangements corresponding to distinct pharmacological 
and functional properties. It has been demonstrated that nAChRs are involved in 
cognitive processes such as learning and memory and control of movement in healthy 
subjects. Recent data from knockout animals have extended the understanding of 
nAChR function. Dysfunction of nAChR has been linked to a number of human 
disorders such as schizophrenia, Alzheimer’s and Parkinson’s diseases (Hogg, R.C et 
al., 2003) 
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Interestingly, there is accumulating experimental evidence that anesthetics also affect 
brain functions on the long term, both in a desirable (preconditioning, neuroprotection) 
and maybe undesirable (neurotoxicity, postoperative cognitive dysfunction, sleep-
wakefulness disorders) with particular sensitivity of the elder brain. These long term 
actions of anesthetics are likely to be mediated by interference with cellular signaling 
going from DNA transcription into RNA to the post-transcriptional regulation of protein 
activity by phosphorylation (J. Mantz and S. Dahmani 2008) 
 
Despite technological advances in surgery and anesthesia during the last few decades, 
the incidence of postoperative cognitive dysfunction remains a relatively common 
complication in surgical patients. After surgery, elderly patients in particular often 
exhibit a transient reversible state of cerebral cognitive alterations. Anesthetics 
administered as part of a surgical procedure may alter the patient’s behavioural state by 
influencing brain activity. This concise report will address the scientific evidence on the 
relationship between postoperative cognitive dysfunctions and the most common 
inhalational agents currently used in anesthesia (P.K Mondal et al., 2009). 
 
Postoperative cognitive dysfunction (POCD) is a decline in a variety of 
neuropsychological domains, especially in memory and executive function, but also is 
characterized by a slowing of brain processing speed. Postoperative cognitive 
dysfunction is a distinct entity from postoperative delirium. The hallmarks of delirium 
are an acute state of confusion with alterations in attention and consciousness. The 
literature is sometimes confusing in that the two terms are sometimes used 
interchangeably leading to imprecision in the discussion of etiologies and potential 
prevention or amelioration of POCD. Though POCD is a common finding after surgery 
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and anesthesia there is currently no ICD-9 code for this disorder or syndrome. 
Postoperative cognitive dysfunction affects both young and old who present for surgery. 
However, the elderly have an increased incidence of this disorder due to less plasticity 
in the aged brain. As the world population ages, the burden imposed by POCD will 
become increasingly more apparent (Szokol JW et al., 2010) 
 
In 2008 a meeting of leading physicians and scientists met in Philadelphia, 
Pennsylvania with the purpose to study the potential relationship between anesthesia 
and the onset and progression of neurodegenerative disorders such as Alzheimer’s 
disease. The consensus statement concluded that there exists sufficient evidence at 
multiple levels to warrant further investigations of neurodegeneration after anesthesia 
and surgery.  
 
Postoperative cognitive deficits are common in adult patients of all ages at hospital 
discharge but only the elderly are at significant risk for long-term cognitive problems. A 
report by the International Study of Postoperative Cognitive Dysfunction (ISPOCD) 
show an international trial of elderly patients (mean age 68 years, range: 60 – 81 years) 
who underwent noncardiac surgery demonstrated a 26% incidence of POCD 1 week 
after surgery, with 10% having persistent POCD 3 months later. Meanwhile younger 
patients (mean age 51 years, range: 40-60 years) showed a lesser incidence at 1 week 
postoperatively (19%) which decreased to 6% after 3 months (P.K Mondal et al., 2009). 
Given that the incidence of POCD is common, it is therefore important to diagnose and 
manage POCD by implementation of validated screening tools and pharmacological 
treatment. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 SEVOFLURANE 
 
Research to develop a safe, non-inflammable inhaled anaesthetic agent began in the 
1930s when chemists discovered that the substitution of fluorine for other halogens 
“lowers the boiling point, increases stability, and generally decreases toxicity” (I. Smith 
et al., 1996). Sevoflurane (fig. 1) was first synthesized in 1968 by Regan at Travenol 
Laboratories, Illinois, while he was investigating a series of halomethyl poly 
fluoroisopropyl ethers. The compound was initially reported by his co-workers in 1971 
(Wallin RF, Napoli MD., 1971). Development was later to be impeded by apparent 
toxic effects, eventually shown to be a consequence of flawed experimental design. 
Baxter Travenol sold the rights to sevoflurane to Anaquest (Ohmeda/BOC), who in turn 
sold these to Maruishi Company. Maruishi continued research and development, 
eventually releasing sevoflurane for clinical use in Japan in May 1990. By the end of 
1993, an estimated 1 million patients had received sevoflurane (Eger EI et al., 1994). 
 
 
 
Figure 2.1:  Chemical Structure Of Sevoflurane (Source : Drugs.Com) 
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Sevoflurane, volatile liquid for inhalation, a nonflammable and nonexplosive liquid 
administered by vaporization, is a halogenated general inhalation anesthetic drug. 
Sevoflurane, is fluoromethyl 2,2,2,-trifluoro-1-(trifluoromethyl) ethyl ether (FDA, 
drugs.com). Sevoflurane is nonpungent, has minimal odor, produce bronchodilation 
similar in degree to isoflurane, and causes the least degree of airway irritation among 
the currently available volatile anaesthesia. For these reason, sevoflurane is acceptable 
for inhalational induction of anaesthesia (Robert K. Stoelting, 2006) 
 
 
Figure 2.2: Sevoflurane Container Label (FDA Drugs.com) 
 
Sevoflurane has little effect on normal myocardial blood flow, is a less potent coronary 
arteriolar dilator than isoflurane, and does not appear to cause “coronary steal” (Kersten 
JR et al., 1994). In contrast with other halogenated ethers, sevoflurane appears to be 
associated with a lower heart rate which helps to reduce myocardial oxygen 
consumption and assists myocardial perfusion (Frink EJ jr et al., 1992).  Sevoflurane 
has CNS effects similar to those of isoflurane and desflurane. Intracranial pressure 
increases at high inspired concentrations of sevoflurane however, this effect is minimal 
over the 0.5–1-MAC range (Scheller MS et al., 1998). 
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Sevoflurane is currently considered the inhalational agent of choice for adult and 
paediatric anaesthesia. Sevoflurane is an ether inhalation general anaesthetic agent with 
lower solubility in blood. The low solubility and the absence of pungency facilitate 
rapid mask induction; the low blood solubility also expedites "wash-out' and therefore 
recovery from anaesthesia (Patel, S.S., Goa, K.L., 1996).  The pharmacodynamic effects 
of sevoflurane on the various organ systems appear to be similar to those of other 
commonly used halogenated ethers. Sevoflurane produces dose-dependent ventilatory 
depression and also reduces respiratory drive in response to hypoxia and increases in 
carbon dioxide partial pressure, comparable with levels achieved with other ether 
anaesthetics (Doi M., et al., 1994) 
 
Boiling point 58.6 °C (at 101.325 kPa) 
Density 1.517–1.522 g/cm³ (at 20 °C) 
MAC 2.1 vol %  
Molecular weight 200 u    
Vapor pressure 157 mmHg (22.9 kPa) 
197 mmHg (26.3 kPa) 
317 mmHg (42.3 kPa) 
(at 20 °C) 
(at 25 °C) 
(at 36 °C) 
Blood:Gas  
partition coefficient 
0.68    
Oil:Gas  
partition coefficient 
47  
 
Table 2.1: Sevoflurane Physical Properties  
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The low blood:gas solubility of sevoflurane should permit rapid elimination from the 
CNS. When sevoflurane and isoflurane were compared as anaesthetic maintenance 
agents after induction of anaesthesia with midazolam and thiopentone in healthy 
patients undergoing elective operations, the average times from end of anaesthesia to 
eye opening on command were 18.6-2.0 min for isoflurane and 7.5-0.5 min for 
sevoflurane (Frink EJ jr et al., 1992). When propofol was used as the induction agent 
before operations lasting approximately 2.5 h, emergence from sevoflurane–nitrous 
oxide anaesthesia (4.1-2.2 min) was still significantly more rapid compared with 
isoflurane–nitrous oxide (6.7 2.2 min) (Smith I, et al., 1992). 
 
Sevoflurane was associated with faster emergence compared with isoflurane using a 
similar technique for gynaecological operations of shorter duration, suggesting that the 
use of intraoperative opioid analgesics may have masked differences between the two 
groups in the former study, which also involved very small numbers of patients (Quinn 
AC, et al., 1994). Rapidly eliminated anaesthetic agents are used most commonly for 
day-case anaesthesia, where rapid, clear-headed recovery may allow for earlier 
discharge of patients. 
 
Rapid recovery compared with halothane, and smooth and calm emergenced are also 
advantageous in children. For adults, the relative insolubility of sevoflurane should 
facilitate control of anaesthetic depth during the maintenance period, even at low gas 
flows. Rapid emergence from anaesthesia with sevoflurane facilitates more efficient 
patient turnover and may confer additional benefits after more prolonged anaesthesia   
(I. Smith et al., 1996). 
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Figure 2.3: Example Bottle Of Sevoflurane  
 
Sevoflurane is a comparatively unstable molecule. It undergoes a moderate degree of 
metabolism (approximately 5 %) and also breaks down in the presence of soda lime and 
Baralyme at elevated temperatures (Strum DP et al., 1987). Both processes result in 
potentially toxic products. However, unlike other anaesthetic ethers, sevoflurane does 
not possess a CF2H group, and so (similar to halothane) does not result in the 
production of carbon monoxide in association with excessively dry carbon dioxide 
absorbants (Fang ZX et al., 1995).  
 
Sevoflurane is absorbed and degraded by both soda lime and Baralyme. When 
sevoflurane is mixed with soda lime, sealed in a flask and heated, a total of five 
breakdown products are produced. These have been designated as compounds A, B,C, 
D and E (Brown BR et al., 1992). Concern has been raised because these products are 
toxin in rats. The evidence suggests that the concentration of compound A achieved in 
clinical practice is well below the concentration which is toxic to animals. 
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The effects of this drug in relation to the incidence of POCD have been investigated, but 
the results are not so clear. In their study on patients undergoing coronary bypass graft 
surgery, (Kadoi et al., 2007) found no relationship between POCD and the use of this 
anaesthetic agent. In contrast some comparative studies of sevoflurane and other 
volatile anesthetics, such as desflurane and isoflurane, indicate that the former seems to 
be associated with the worst cognitive outcomes (Kanbak et al., 2005). For instance, it 
is clear that sevoflurane increases tau and P- tau level in the cerebrospinal fluid of 
surgical patients for at least 48 hours. Tau hyperphosphorylation might be a mechanistic 
bridge linking between anesthesia and the risk of cognitive impairment. 
 
The effects of sevoflurane anesthesia on POCD have also been evaluated in comparison 
with intravenous anesthesia with propofol, highlighting how the incidence of POCD 
levels does not depend on the anesthetic agent used (Rohan, D et al., 2005). Moreover, 
total intravenous anesthesia with propofol/remifentanil- shows no patient benefit over 
sevoflurane/fentanyl-based anesthesia in terms of recovery and cognitive functions 
(Magni, G et al., 2005).  
 
Although halogenated agents are thought to have limited effects on POCD, sevoflurane 
anesthesia has been shown to alter exploratory and anxiety-like behavior in animals 
with a genetically modified cholinergic system (Wiklund A et al., 2008). Data showed 
sevoflurane promote tau phosphorylation even in normothermic conditions. 
Dysregulation of this phosphorylation/dephosphorylation balance involved in these key 
physiologic neuronal pathways may thus be impaired in sevoflurance condition (Helene 
L.F et al., 2012). 
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2.2. TAU PROTEIN 
 
2.2.1     Tau Overview 
Neurons are cells with a very complex morphology that develop two types of 
cytoplasmic extensions, axons and dendrites. Neural transmission occurs through these 
processes, and therefore, any changes in neuronal morphology may affect their behavior 
and even produce pathological events. Indeed, it should be born in mind that the 
morphological differentiation of a neuron involves the extensive rearrangement of the 
cytoskeleton, which is responsible for maintaining the cell's shape (Esus A. et al 2003). 
 
The cytoskeleton is composed of three main components: the microtubules, the 
microfilaments, and the intermediate filaments. Microtubules are very dynamic 
structures, and in proliferating cells such as neuroblasts (neuron precursors), their 
probability of assembly is the same as that of depolymerization in all directions. This 
equilibrium results in the cell maintaining a spherelike morphology. However, during 
the differentiation of a neuroblast into a neuron, the microtubules become stabilized in 
specific directions, thereby generating the cytoplasmic extensions that will become the 
axon and the dendrites (Mitchison T and Kirschner M 1988).  
 
It has been suggested that specific proteins may serve to stabilize microtubules and such 
proteins including the microtubule-associated proteins (or MAPs) MAP1A, MAP1B, 
MAP2, and tau. In support of this hypothesis, an asymmetric distribution of MAPs is 
seen in mature neurons, and tau is preferentially localized in axons (Binder LI et al., 
1985). Furthermore, in pathological situations, tau has additionally been shown to be 
capable of forming aberrant fibrillar polymers. 
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Figure 2.4: J. Avila - Tau is a microtubule-associated protein that stabilizes 
microtubules and that is able to self-aggregate in pathological conditions. A: the ectopic 
expression of tau in nonneural cells (a and b) promotes the stabilization of microtubules, 
leading to the formation of cytoplasmic extensions (arrows) that are not normally seen 
in those cells that are not expressing tau (c). B: scheme showing tau as a microtubule-
associated protein (the size of the tau molecule is exaggerated compared with that of the 
microtubule). A view of the binding of tau to a tubulin dimer is indicated. C: in 
pathological situations (like Alzheimer's disease), the tau protein can form aberrant 
filaments (a). These filaments can bind to antibodies raised against the tau protein (b) 
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Tau proteins are microtubule-associated proteins that are found abundant in neurons in 
the central nervous system. Tau proteins were discovered in 1975 in Marc Kirschner’s 
laboratory at Princeton University. Tau protein belongs to a group of proteins referred 
to as Microtubule-Associated Proteins (MAPs), that in common are heat resistant and 
limited affected by acid treatment without loss their function (D. W. Cleveland et al., 
1977).  
 
The human tau gene is located over 100 kb on the long arm of chromosome 17 at band 
position 17q21 and contains 16 exons. Exon 1 is part of the promoter and is transcribed 
but not translated. Exons 1, 4, 5, 7, 9, 11, 12, and 13 are constitutive exons. Exons 2, 3, 
and 10 are alternatively spliced and manifesting in the adult brain. Exon 2 can appear 
alone, but exon 3 never appears independently of exon 2. In the central nervous system, 
alternative splicing of exons 2, 3, and 10 results in the appearance of six tau isoforms 
that are differentially expressed during development of the brain (N. Sergeant et al., 
2005) 
 
Figure 2.5: Tau Protein Structure (Picture Courtesy from http://www.ebi.ac.uk/) 
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Tau proteins can interact with tubulin to stabilise microtubules and promote tubulin 
assembly into microtubules. There are two ways for Tau protein to control microtubule 
stability: isoforms and phosphorylation.  Two different tau gene halotypes have been 
identified (H1 and H2) consisting of 2 common single nucleotide polymorphisms. H1 is 
the most common, and it is overexpressed in disorders like progressive supranuclear 
palsy and corticobasal degeneration.  
 
In the brain tissue, there are six Tau isoforms that exist in the brain tissue, and are 
distinguished by their number of binding domains. There are three isoforms that have 
three binding domains and the other three have four binding domains. The binding 
domains are located in the carboxy-terminus of the protein and are positive-charged, 
allowing it to bind to the negative-charged microtubule. The isoforms with four binding 
domains are better at stabilising microtubules than those with three binding domains. 
The isoforms are a result of alternative splicing in exons 2, 3 and 10 of the Tau gene. 
Phosphorylation of Tau is regulated by a host of kinases, for example, Protein Kinase 
N1 (PKN), a serine/threonine kinase. 
 
 
 
Figure 2.6: Six Major Tau Isoforms In Human Brain - Susanna Schraen 
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Tau Proteins can be used as biomarkers of brain pathology and as peripheral biomarkers 
of neurodegenerative diseases (S Schraen-Maschke et al., 2008). Pathological tau may 
participate in the localization of Fyn kinase to the postsynaptic compartment, where it 
phosphorylates NMDAR subunits, causing increased inward Ca2+ conductance and 
leading to excitotoxity (S. M. Pritchard et al., 2011). 
 
Impaired interaction of Fyn kinase and hyperphosphorylated tau protein leads to 
hypomyelination and evolving demyelination of axons (C. Klein et al., 2002). All these 
evidences indicate that the phosphorylated state of tau protein not only affects 
microtubule stability but also produces alterations on neuronal plasticity 
 
 
 
Figure 2.7: Structure Of Normal Tau Proteins And Alzheimer’s Disease 
Microtubules With Neurofibrillary Tangle. 
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When tau proteins are defective, and no longer stabilize microtubules properly, they can 
result in dementias such as Alzheimer's disease. (Tan et al., 2010) illustrated that 
increased cytokine levels after surgery leads to phosphorylation of tau protein and the 
formation of neurofibrillary tangles that associated with Alzheimer’s disease. Whether 
these changes are serious enough to elicit neurodegeneration or cause a more subtle 
change in neuronal function remains to be determined 
 
 
  
 
Figure 2.8: Stages In The Neuropathology Of Alzheimer’s Disease. Implication For 
The Use Of Tau As Biomarker During The Course Of The Disease- Susanna 
Schraen 
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2.3 BRAIN DERIVED NEUROTROPIC FACTOR 
 
Neurotrophins are an important class of signaling molecules in the brain responsible for 
axon targeting, neuron growth, maturation of synapses during development, and 
synaptic plasticity. This family of molecules includes nerve growth factor (NGF1) 
(Levi-Montalcini, 1966), brain-derived neurotrophic factor (BDNF) (Barde et al., 
1982), as well as neurotrophins 3 and 4 (Hohn et al., 1990). Of these, BDNF is the best 
characterized in terms of its role in synaptic plasticity (Lohof et al., 1993; Levine et al., 
1995, 1998; Kossel et al., 2001) and its potential role in the disease pathology or 
treatment of many psychiatric diseases (Duman and Monteggia 2006). 
 
Brain derived neurotrophic factor (BDNF) is the most prevalent growth factor in the 
central nervous system (CNS). It is essential for the development of the CNS and for 
neuronal plasticity. Because BDNF plays a crucial role in development and plasticity of 
the brain, it is widely implicated in psychiatric diseases. The BDNF gene (in humans 
mapped to chromosome 11p) has four 5′ exons (exons I-IV) that are associated with 
distinct promoters, and one 3′ exon (exon V) that encodes the mature BDNF protein 
(Metsis et al., 1993). 
 
Figure 2.9: Brain-Derived Neurotrophic Factor (Wikipaedia 2013) 
 
 
17 
BDNF acts on certain neurons of the central nervous system and the peripheral nervous 
system, helping to support the survival of existing neurons, and encourage the growth 
and differentiation of new neurons and synapses. In the brain, it is active in the 
hippocampus, cortex, and basal forebrain areas vital to learning, memory, and higher 
thinking. BDNF itself is important for long-term memory. This gene may play a role in 
the regulation of stress response and in biology of mood disorders (Wikipaedia 2013). 
 
BDNF is synthesized as a precursor protein known as prepro-BDNF that is cleaved into 
pro-BDNF, which can then be further cleaved into mature BDNF (Lessmann et al., 
2003). Pro-BDNF and mature BDNF activate different intracellular signaling pathways 
(Woo et al., 2005; Matsumoto et al., 2008; Yang et al., 2009). Pro-BDNF signals 
through the low-affinity neurotrophin receptor p75 that is believed to be involved in 
apoptosis (Roux and Barker, 2002; Lessmann et al., 2003). Mature BDNF signals 
through its high-affinity tropomyosin-related kinase B (TrkB) receptor. When BDNF is 
bound to TrkB, it induces its dimerization and the receptor tyrosine kinase is 
autophosphorylated, leading to activation of intracellular signaling cascades, as well as 
augmentation of N-methyl-d-aspartate (NDMA) receptor currents (Levine et al., 1998). 
 
There are at least three signaling transduction pathways that BDNF-TrkB activation can 
regulate. The phospholipase C γ (PLC γ) pathway, which leads to activation of protein 
kinase C; the phosphatidylinositol 3-kinase (PI3K) pathway, which activates 
serine/threonine kinase AKT; and the mitogen-activated protein kinase [MAPK, or 
extracellular signal related kinase (ERK)] pathway, which activates several downstream 
effectors. Each of these signaling pathways confer the unique function of BDNF on 
cells (Mattson et al., 2008).  
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Figure 2.10: Overview Of BDNF Signaling Through Trkb Receptors 
 
BDNF alone may not be sufficient to explain depression-related behaviors, but it 
remains an important risk factor for depression. Researchers have examined the role that 
BDNF plays in susceptibility to developing stress-related mood disorders, but 
preclinical investigations have not yet demonstrated how loss of BDNF alters 
vulnerability to stress (Advani et al., 2009). 
 
BDNF and NGF are important in the development, survival and maintenance of neurons 
in the central nervous system. The hippocampus has a key role in memory and spatial 
location since it is an important area of the brain required for learning and memory. 
Previous studies have demonstrated that the downregulation of BDNF and NGF in the 
brain may result in memory and learning deficits (Conner JM et al., 2009). 
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Brain-derived neurotrophic factor number of studies has suggested that there is a strong 
link between volatile anesthetics, for example isoflurane, and cognitive impairment 
(Callaway Jk et al., 2012, Lin D et al., 2011). BDNF and NGF are important in the 
development, survival and maintenance of neurons in the central nervous system 
(Henriksson BG et al., 1992). The hippocampus has a key role in memory and spatial 
location since it is an important area of the brain required for learning and memory. 
Previous studies have demonstrated that the down regulation of BDNF and NGF in the 
brain may result in memory and learning deficits (Conner JM et al., 2009). 
 
BDNF is involved in development, neurotransmission, and is also reactive to 
environmental stimuli it has been studied in the pathophysiology of Schizophrenia. It 
has been proposed that developmental abnormalities, as well as persistent cognitive and 
emotional dysfunction that occur in development, including circuit-level, genetic, or 
environmental alterations in BDNF expression, lead to pathological behavioral and 
neuronal features associated with schizophrenia (Durany and Thome, 2004). Post 
mortem studies of schizophrenia brain tissue have demonstrated alterations in BDNF in 
certain brain regions.  
 
Various studies have shown possible links between BDNF and conditions such as 
depression, bipolar disorder, schizophrenia, obsessive-compulsive disorder, Alzheimer's 
disease, Huntington's disease, Rett syndrome, and dementia, as well as anorexia nervosa 
and bulimia nervosa (Zuccato C et al., 2001). 
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2.4 POSTOPERATIVE COGNITIVE DISORDER 
 
Post-operative cognitive dysfunction (POCD) is a severe complication characterized by 
cognitive decline in patients following anesthesia and surgery. Previous studies have 
suggested that volatile anesthetics, for example isoflurane, may contribute to such 
impairment (Zhang F. et al., 2014). POCD may be self-limiting in the majority of 
patients; however, it may affect the prognosis and life quality of certain individuals 
(Steinmetz J, et al., 2009). 
 
Postoperative cognitive changes have been reported in elderly patients for over a 
century, and anesthesia has often been mentioned as a possible cause of this problem. In 
1955, Bedford published a retrospective review of 1193 elderly patients who had 
surgery under general anesthesia during a 5-year period. He found that cognitive 
problems occurred in approximately 10% of older patients after surgery. Most of these 
patients experienced mild problems after surgery (inability to write a decent letter, 
concentrate, go shopping alone or read a book, increased forgetfulness after surgery, 
unable to attend to business), but were still able to function independently. 
 
In a retrospective analysis of the International Study for Postoperative Cognitive 
Dysfunction (ISPOCD) research data, patients with postoperative delirium had a higher 
incidence of POCD one week postoperatively (Rudolph JL et al., 2008). Although the 
ISPOCD results seem to suggest that postoperative delirium and POCD appear to be 
discrete events, other research provides support to the continuum hypothesis, 
specifically, that POCD is a subclinical from of delirium. 
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The exact pathophysiology of POCD remains undefined. Several mechanisms have 
been proposed to be involved in the development of cognitive impairments after 
surgery, including changes in cerebral blood flow, sleep disturbances, effects of 
anaesthetics, and inflammation. Hypoperfusion, hypoxia and the formation of micro-
emboli have been shown to occur during and after surgery, and could potentially cause 
ischaemic brain damage, but a clear relationship with POCD has not been found (Krenk 
et al., 2010). 
 
The main risk factors for perioperative cognitive change are well recognized: 
 
1. Non pharmacological factors: 
• Increasing age 
• Poor cognitive impairment 
• Low educational level 
• Depression 
 
2. Intraoperative factors: 
• Cardiac surgery 
• Longer anaesthetic administration 
 
3. Postoperative factors: 
• Poorly controlled pain 
• Postoperative wound infection 
• Reoperation within 1 week of original operation 
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POCD is a subtle impairment of memory, concentration, and information processing 
that is distinct from delirium and dementia. Despite the fact that POCD is not a formal 
psychiatric diagnosis, the term is commonly used in the literature and is considered to 
be a mild neurocognitive disorder (Terri G. and Catherine C. 2011). The DSM-IV 2000 
states that a mild neurocognitive disorder can only be diagnosed if the cognitive 
disturbance does not meet the criteria for three other conditions (delirium, dementia, or 
amnestic disorder). Post-operative cognitive disorders is different with postoperative 
delirium which tends to be a transient and fluctuating disturbance of consciousness that 
tends to occur shortly after surgery whereas post-operative cognitive disorders is a more 
persistent problem of a change in cognitive performance as assessed by 
neuropsychological tests (Newman et al., 2007). 
 
Postoperative cognitive dysfunction affects both young and old who present for surgery; 
however, the elderly have an increased incidence of this disorder due to less plasticity in 
the aged brain (Joseph W. Szokol et al., 2010). POCD (Postoperative cognitive 
dysfunction) can cause catastrophic loss of cognitive function, with associated increased 
mortality, risk of losing job & dependence of social welfare. (Steinmetz JC et al., 2009). 
 
The clinical significance of POCD, particularly in older individual, is emphasised by 
evidence of the impact it confers on the ability to perform daily activities (Kojima Y, 
Narita M 2006). POCD is most common after cardiac surgery although up to 40% of 
people are affected for one week after non-cardiac procedures. Importantly, up to 15% 
of people continue to be affected after three months (Newman S et al., 2007). 
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Several studies indicate that volatile anesthetics influence brain function and 
development beyond the time of anesthesia (Jevtovic-Todorovic V et al., 2003). 
Further, clinical experience suggests that some patients have remnant symptoms after 
general anesthesia, including a broad range of neurocognitive dysfunction, though 
clinical studies have not found long-lasting effects of volatile anesthetics (Chen X et al., 
2001). 
 
Volatile anesthetics affect cerebral bloodflow and metabolism (Lenz C et al., 1998), and 
signaling via γ-aminobutyric acid receptors, N-methyl-d-aspartate receptors, and 
voltage-gated sodium channels (Ratnakumari L et al., 2000). These effects occur during 
anesthesia, but not for later periods after withdrawal of anesthetic gases. These and 
other effects suggest that volatile anesthetics can have profound effects on cellular 
function, as well as altering expression at the message and protein levels (Kapinya KJ et 
al., 2002). Sevoflurane induced relevant changes in protein expression profiles directly 
and 72 h after an anesthesia with 1 MAC (Kalenka et al., 2007). 
 
Several studies have found general anesthesia without surgery in old rodents induces 
prolonged changes in gene and protein expression and learning impairment that lasts 
days to weeks, implying either that the neurobiological machinery of memory is altered 
in an enduring way or that damage occurs (Culley DJ et al., 2007). In addition, there is 
evidence that some volatile anesthetics promote processes implicated in the 
neuropathogenesis of Alzheimer’s disease (Tang J et al., 2009). Due to the subtle nature 
of POCD, it is often only the patient and/or partner who recognize the onset of this 
problem. The symptoms vary from mild memory loss to an inability to concentrate or 
process information. 
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The concept of cerebral cognitive reserve is often cited to explain why individuals with 
a similar degree of cerebral insult often have significant differences in the degree of 
cognitive symptoms. (Satz P et al., 1993) described a concept of brain reserve, which 
may help to explain vulnerability to postoperative cognitive problems: greater brain 
reserve serves as a protective factor, whereas less brain reserve serves as a vulnerability 
factor to a lesion or pathology.  
 
 
 
In the figure 2.11: Patient A has greater reserve (which can be measured in a number 
of ways: education level, intelligence, brain size, white matter lesions, etc.) relative to 
patient B. Both patients experience a perioperative insult to the brain that results in a 
similarly sized ‘lesion’. Patient A, however, because of cognitive reserve, does not 
demonstrate postoperative delirium or postoperative cognitive change and remains 
above the critical threshold for identifying a measurable change in functional outcome. 
Patient B with less preoperative cognitive reserve, by contrast, falls below this critical 
threshold and demonstrates significant changes in function which may manifest as 
postoperative delirium or POCD in the postoperative period. 
 
 
